Related Experiment Videos
Protease inhibitor-associated angiolipomatosis
1Department of Medicine, Division of Dermatology, University of Washington-Harborview Medical Center, Seatle 98104, USA.
Journal of the American Academy of Dermatology
|December 22, 1999
Summary
Protease inhibitors used for HIV-1 treatment can cause lipodystrophy. This report details three cases where patients developed symptomatic angiolipomas after starting indinavir, suggesting a link to this antiretroviral therapy.
Area of Science:
- Oncology
- Infectious Diseases
- Endocrinology
Background:
- Antiretroviral therapy (ART) for HIV-1 infection, particularly protease inhibitors (PIs), is linked to lipodystrophy.
- Lipodystrophy includes peripheral lipoatrophy, central adiposity, insulin resistance, and dyslipidemia.
Observation:
- Three cases of HIV-1 infected patients are presented.
- These patients developed symptomatic angiolipomas shortly after initiating ART with indinavir.
- Angiolipomas are uncommon benign tumors of adipose tissue.
Findings:
- The development of symptomatic angiolipomas may be associated with protease inhibitor-containing ART.
- The underlying mechanism could be similar to other PI-associated fat redistribution syndromes.
- This involves adipose tissue within benign tumors rather than generalized fat changes.
Implications:
- This finding expands the known spectrum of adverse effects associated with protease inhibitors in HIV-1 treatment.
- Clinicians should be aware of the potential for angiolipoma development in patients on specific ART regimens.
- Further research is warranted to elucidate the precise mechanism linking PIs and angiolipoma formation.